C4 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 145
- Market Cap
- $445.8M
- Introduction
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
- Conditions
- Solid TumorsMelanomaNSCLCCRCATC
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- C4 Therapeutics, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05668585
- Locations
- 🇺🇸
University of Arizona - Cancer Center, Tucson, Arizona, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Community Health Network, Indianapolis, Indiana, United States
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- C4 Therapeutics, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05355753
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
- Conditions
- Multiple MyelomaLymphoma, Non-Hodgkin's
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- C4 Therapeutics, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT04756726
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California-San Francisco, San Francisco, California, United States
🇺🇸Colorado Blood Cancer Institute (Sarah Cannon Research Institute), Denver, Colorado, United States